First‐line chemoimmunotherapy for patients with small‐cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis

First‐line chemoimmunotherapy for patients with small‐cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis

Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) receiving immunotherapy face a potential risk of developing checkpoint inhibitor‐related pneumonitis (CIP). However, there is no clear understanding of the specific link between interstitial lung abnormality (ILA) and CIP in patien...

Full description

Bibliographic Details
Main Authors: Yu Li, Yuxin Jiang, Luyun Pan, Jun Yao, Shuo Liang, Yanjun Du, Dong Wang, Hongbing Liu, Fang Zhang, Qin Wang, Tangfeng Lv, Ping Zhan
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Thoracic Cancer
Subjects:
checkpoint inhibitor‐related pneumonitis
chemoimmunotherapy
interstitial lung abnormality
small‐cell lung cancer
survival
Online Access:https://doi.org/10.1111/1759-7714.15471

Internet

https://doi.org/10.1111/1759-7714.15471

Similar Items